Authors

From Lab to Market: Tracking Today’s Shifting Pathways for Biotech

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Fair Market Value vs. Current Market Leverage

How pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution services

Rethinking Market Access in CEE: Time to Bust the Myths

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Your DSCSA Responsibilities

Discover essential guidelines for complying with the Drug Supply Chain Security Act (DSCSA). Learn how to enhance supply chain security and meet regulatory standards across various roles in the pharmaceutical industry.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

The Direct-to-Patient Balance Sheet: Increased Access, Decreased Friction and Trust Earned

DTP programs are redefining the manufacturer’s access operating model.

What is Daiichi Sankyo’s Post JP Morgan Strategy?

In the final part of his conversation with Pharmaceutical Executive, Ken Keller discusses what his expectations are following the healthcare conference.

Turning Abandonment Scenarios into Patient Starts

Discover three strategies for overcoming high costs, prior authorization delays and rejected claims.

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Proactive Engagement: How AI-Driven Alerts are Transforming HCP Outreach

The benefits for brand teams in bolstering their rapid-response capability.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

From Uncertainty to Opportunity: Navigating IPAY 2028

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Your Trusted Resource for Mission Critical Solutions

There’s a reason your facility’s most sensitive operations are called “mission critical.” Learn how ABM’s highly technical management services can take the worry out of maintaining your most specialized systems.

Introducing Agentic AI: Its Revolutionary Potential in Pharma

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

AI Can’t Lead. Healthcare Needs Leaders

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

Why Healthcare Costs are Surging—And What to Do About it

Identifying the inflators and deflators, and the role all stakeholders play.

Advancing Circular Economy Packaging in Pharmaceutical Cold Chain

Site Satisfaction Is the New Competitive Advantage

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

TrumpRx’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Beyond Awareness: Modeling Shared Decision-Making in Patient Communications

When patients struggle to see a positive path forward, modeling a constructive journey can give them the confidence they need.

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

AI in Drug Discovery On-Demand Webinar

Revolutionizing Pharma Patient Assistance Programs, KnippeRx Leads the Future of Patient Care

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Shifting Pharmacy Landscape in 2025

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.